Previous close | 4.71 |
Open | 4.61 |
Bid | 4.95 x 100 |
Ask | 5.18 x 100 |
Day's range | 4.53 - 5.11 |
52-week range | 0.22 - 5.11 |
Volume | |
Avg. volume | 318,446 |
Market cap | 43.828M |
Beta (5Y monthly) | 2.18 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.27 |
Earnings date | 22 May 2024 - 29 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, today announced that on March 13, 2024 it received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market Inc. ("Nasdaq") indicating that the Company had regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requirement").